Comecer becomes a member of the CNIC

On September 18th, 2019 Comecer joined the Canadian Nuclear Isotope Council (CNIC), an independent organization to promote Canada’s role in the production of the world’s supply of radioisotopes.

 

Here below is the full text of the CNIC press release.

 

“Comecer joins the Canadian Nuclear Isotope Council to advance human health and help save lives. World leader in design and manufacturing of high-technology systems in radiopharma, pharma and regenerative medicine will collaborate with CNIC to enhance Canada’s leadership in the field of nuclear medicine and isotopes.

Toronto, September 18, 2019 – Comecer, a world leader in the design and manufacturing of equipment for the safe treatment of radioactive substances in nuclear medicine has joined a growing list of organizations as members of the Canadian Nuclear Isotope Council (CNIC) an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research groups, the CNIC was convened to promote Canada’s role in the production of the world’s supply of radioisotopes.

“Any patient needing medical isotopes for diagnostic purposes is usually scheduled for a nuclear scan (which includes all types of imaging techniques that use radioactivity). Scans are particularly suitable for detecting movement and change, such as blood flow through the heart or metabolism of an organ,” said Alessia Zanelli, President of Comecer. “Comecer is a leader in the field of radiochemistry and in the nuclear medicine market where our products can be found in the most advanced and prestigious research centres, universities, hospitals and pharmaceutical companies worldwide. Joining the CNIC to promote the safe use and continued reliability of supply of isotopes to the world markets is a natural fit with our values.” The world’s supply of research reactor-based isotopes is currently being challenged, as many facilities are reaching their end of life, at a time when their importance and value to the health-care community is reaching new levels through research and innovation in this space. Reliability and affordability of radioisotope supply will be critical to patients who depend on their treatments being available.
“Medical isotopes are very important, particularly for diagnostic purposes in oncology; cardiology and neurology estimated that more than 10,000 hospitals worldwide use isotopes for diagnosis,” said James Scongack, Chair of the Canadian Nuclear Isotope Council. “Having partners like Comecer is paramount to Canada’s radioisotope innovations continuing to serve as a model for leadership, using science to find solutions to real world challenges.
“Our achievements in cancer treatment would not have been possible without the National Research Universal (NRU) reactor and the brilliant Canadian scientists and technical experts who designed and built marvels in engineering. As we celebrate the contributions of Canada’s innovative nuclear scientists, we are confident we will continue to build a better tomorrow.”

To ensure that Canadians benefit from recent advances in nuclear medicine, Canada must build and maintain a domestic supply of both established and emerging medical isotopes, and strengthen its ability to convert raw isotopes into clinical-quality products. The CNIC will remain focused on ensuring that Canada continues to be a world leader in the production of life-saving isotopes by bringing awareness and supporting long-term policies at the domestic and international levels that will save countless lives and support health-care innovation for decades to come.

The CNIC is a coalition of science, health care and nuclear sector organizations to ensure Canada remains a world leader in the production of life-saving isotopes by bringing awareness and supporting long-term policies at the domestic and international level that will save countless lives and support health-care innovation for decades to come.

To learn more about the CNIC visit www.canadianisotopes.ca“.

 

To read and download a pdf copy of this press release, click here.

 

 

 

For further information from Comecer regarding this press release, fill out the form below:

Have questions?

Open


I have read and understood the information sheet pursuant to Art. 13 GDPR.
I express my consent also for the processing of my personal data for profiling purposes and for the analysis of the preferences, interests and habits, as indicated in the section “Data processed and Purposes of processing” of the Privacy Policy published on the website.
 
 
COMECER NEWSLETTER SIGNUP 
I express my consent to process my personal data for marketing purposes and the sending of promotional and informative material, including newsletters and commercial communications concerning Comecer products/services, as indicated in the section “Data processed and Purposes of processing” of the Privacy Policy published on the website.
 
 
Please select your categories of interest:
 
 
 
 
 
Cancel

Necessary

Chiudi

Cancel

Statistics

Chiudi

Cancel

Targeting

Chiudi